RECRUITING

Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Demonstrate the feasibility of conducting an eight-week, (45 min/week), theory driven, virtually-delivered, tailored music-based relaxation (TiMBRe) intervention to decrease anxiety in adolescent and young adult (AYA) cancer survivors with clinically-relevant anxiety.

Official Title

Determining the Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors

Quick Facts

Study Start:2025-04

Study Completion:2030-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05911269

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 39 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* 15 - 39 years old * at least one month post cancer treatment * report clinically relevant anxiety in the past seven days (PROMIS Anxiety 4a scores ≥ 55)35 * speak/read English.	* prognosis less than 3 months * documentation of significant hearing impairment * plan to receive surgery, radiation, or chemotherapy for cancer treatment during the study period * plans in place to begin new psychosocial (i.e., cognitive behavioral therapy14 or mindfulness-based stress reduction15) or pharmacological treatments for anxiety during the study. Although, participants may continue psychosocial or pharmacological treatments for anxiety if the treatments were initiated at least eight weeks prior to study enrollment, the dose has not changed, and they report clinically relevant anxiety in the last week.

Inclusion Criteria

Exclusion Criteria

* 15 - 39 years old
* at least one month post cancer treatment
* report clinically relevant anxiety in the past seven days (PROMIS Anxiety 4a scores ≥ 55)35
* speak/read English.

* prognosis less than 3 months
* documentation of significant hearing impairment
* plan to receive surgery, radiation, or chemotherapy for cancer treatment during the study period
* plans in place to begin new psychosocial (i.e., cognitive behavioral therapy14 or mindfulness-based stress reduction15) or pharmacological treatments for anxiety during the study. Although, participants may continue psychosocial or pharmacological treatments for anxiety if the treatments were initiated at least eight weeks prior to study enrollment, the dose has not changed, and they report clinically relevant anxiety in the last week.

Contacts and Locations

Study Contact

Robert Knoerl

CONTACT

734-764-8617

rjknoerl@med.umich.edu

Principal Investigator

Robert Knoerl

PRINCIPAL_INVESTIGATOR

University of Michigan Rogel Cancer Center

Study Locations (Sites)

University of Michigan

Ann Arbor, Michigan, 48118

United States

Collaborators and Investigators

Sponsor: University of Michigan Rogel Cancer Center

Robert Knoerl, PRINCIPAL_INVESTIGATOR, University of Michigan Rogel Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04

Study Completion Date2030-06

Study Record Updates

Study Start Date2025-04

Study Completion Date2030-06

Terms related to this study

Additional Relevant MeSH Terms

Anxiety